Rituximab to treat prolidase deficiency due to a novel pathogenic copy number variation in PEPD
Prolidase deficiency (PD) is a rare autosomal recessive inborn error of immunity caused by biallelic homozygous or compound heterozygous loss-of-function mutations in PEPD, the gene that encodes prolidase. PD typically manifests with variable dysmorphic features, chronic cutaneous ulcers, recurrent...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-10-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/9/4/e003507.full |